Neoadjuvant Oncolytic Virus orienx010 and Toripalimab in Resectable Acral Melanoma: A Phase Ib Trial

This Phase Ib trial study assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable acral melanoma (AM). Neoadjuvant ori and tori demonstrated antitumor activity with high response rates for AM with acceptable tolerability.